KCM
MYGN icon

Karp Capital Management’s Myriad Genetics MYGN Stock Holding History

Karp Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$3K – 282
2018
Q4 		$3K Buy
+100
New +$3.6K ﹤0.01% 316
2015
Q4 		– Sell
-100
Closed -$4K – 221
2015
Q3 		$4K Hold
100
– – ﹤0.01% 304
2015
Q2 		$3K Hold
100
– – ﹤0.01% 342
2015
Q1 		$4K Hold
100
– – ﹤0.01% 313
2014
Q4 		$3K Buy
+100
New +$3.55K ﹤0.01% 319

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Karp Capital Management's MYGN Position: Q1 2019 in Review

Karp Capital Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 100 shares — an estimated $3K sold.

Karp Capital Management first reported a position in MYGN in Q4 2014 and held it in 5 quarters. The position peaked at $4K in Q3 2015. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • Karp Capital Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
  • Karp Capital Management sold 100 Myriad Genetics shares in Q1 2019, an estimated $3K.
  • Karp Capital Management first reported a position in Myriad Genetics in Q4 2014 and held it in 5 quarters.
  • Karp Capital Management's Myriad Genetics position peaked at $4K in Q3 2015.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Karp Capital Management's 13F filing for Q1 2019, filed 7 May 2019.